SHSE:600196 (China)
Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd
NAICS : 325412
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Compare
Compare
Traded in other countries / regions
600196.China
•
08HH.Germany
•
02196.Hong Kong
•
SFOSF.USA
Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices and medical diagnosis, Pharmaceutical distribution and retail, and Other business operations. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.53 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.7 | |||||
| Debt-to-EBITDA | 4.04 | |||||
| Interest Coverage | 3.41 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.28 | |||||
| Beneish M-Score | -2.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.7 | |||||
| 3-Year EBITDA Growth Rate | 13.9 | |||||
| 3-Year EPS without NRI Growth Rate | 20 | |||||
| 3-Year FCF Growth Rate | -65 | |||||
| 3-Year Book Growth Rate | 11.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 11.87 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.26 | |||||
| 9-Day RSI | 42.27 | |||||
| 14-Day RSI | 43.31 | |||||
| 6-1 Month Momentum % | 12.17 | |||||
| 12-1 Month Momentum % | -29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.84 | |||||
| Cash Ratio | 0.46 | |||||
| Days Inventory | 89.95 | |||||
| Days Sales Outstanding | 52.59 | |||||
| Days Payable | 70.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.3 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| 3-Year Dividend Growth Rate | 4.2 | |||||
| Forward Dividend Yield % | 1.3 | |||||
| 5-Year Yield-on-Cost % | 1.64 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.28 | |||||
| Operating Margin % | 6.81 | |||||
| Net Margin % | 10.53 | |||||
| ROE % | 11.33 | |||||
| ROA % | 4.79 | |||||
| ROIC % | 2.86 | |||||
| ROC (Joel Greenblatt) % | 43.65 | |||||
| ROCE % | 10.6 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.41 | |||||
| Forward PE Ratio | 24.62 | |||||
| PE Ratio without NRI | 25.17 | |||||
| Shiller PE Ratio | 33.3 | |||||
| Price-to-Owner-Earnings | 111.43 | |||||
| PEG Ratio | 2.49 | |||||
| PS Ratio | 2.67 | |||||
| PB Ratio | 2.89 | |||||
| Price-to-Tangible-Book | 7.57 | |||||
| Price-to-Operating-Cash-Flow | 27.13 | |||||
| EV-to-EBIT | 17.69 | |||||
| EV-to-Forward-EBIT | 45.87 | |||||
| EV-to-EBITDA | 17.69 | |||||
| EV-to-Forward-EBITDA | 24.61 | |||||
| EV-to-Revenue | 2.83 | |||||
| EV-to-Forward-Revenue | 2.76 | |||||
| EV-to-FCF | -104.71 | |||||
| Price-to-Projected-FCF | 5.13 | |||||
| Price-to-DCF (Earnings Based) | 1.35 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Graham-Number | 2.91 | |||||
| Earnings Yield (Greenblatt) % | 5.65 | |||||
| Forward Rate of Return (Yacktman) % | 4.06 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 41,330.906 | ||
| EPS (TTM) (¥) | 1.7 | ||
| Beta | 1.41 | ||
| Volatility % | 48.57 | ||
| 14-Day RSI | 43.31 | ||
| 14-Day ATR (¥) | 1.451282 | ||
| 20-Day SMA (¥) | 44.509 | ||
| 12-1 Month Momentum % | -29 | ||
| 52-Week Range (¥) | 37.18 - 71.74 | ||
| Shares Outstanding (Mil) | 2,669.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Fosun Pharmaceutical (Group) Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||